AZD2171 : A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancerWEDGE, Stephen R; KENDREW, Jane; CHESTER, Rosemary et al.Cancer research (Baltimore). 2005, Vol 65, Num 10, pp 4389-4400, issn 0008-5472, 12 p.Article

Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-SrcPLE, Patrick A; GREEN, Tim P; HENNEQUIN, Laurent F et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 4, pp 871-887, issn 0022-2623, 17 p.Article

N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitorHENNEQUIN, Laurent F; ALLEN, Jack; OTTERBEIN, Ludovic et al.Journal of medicinal chemistry (Print). 2006, Vol 49, Num 22, pp 6465-6488, issn 0022-2623, 24 p.Article

Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitorsHENNEQUIN, Laurent F; STOKES, Elaine S. E; THOMAS, Andrew P et al.Journal of medicinal chemistry (Print). 2002, Vol 45, Num 6, pp 1300-1312, issn 0022-2623Article

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administrationWEDGE, Stephen R; OGILVIE, Donald J; GRAHAM, George A et al.Cancer research (Baltimore). 2002, Vol 62, Num 16, pp 4645-4655, issn 0008-5472Article

Inhibitors of epidermal growth factor receptor tyrosine kinase : Optimisation of potency and in vivo pharmacokineticsBALLARD, Peter; BRADBURY, Robert H; WILLIAMS, Emma J et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 18, pp 4908-4912, issn 0960-894X, 5 p.Article

5-substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinaseBALLARD, Peter; BRADBURY, Robert H; HENNEQUIN, Laurent F. A et al.Bioorganic & medicinal chemistry letters (Print). 2005, Vol 15, Num 19, pp 4226-4229, issn 0960-894X, 4 p.Article

Inhibitors of epidermal growth factor receptor tyrosine kinase : Novel C-5 substituted anilinoquinazolines designed to target the ribose pocketBALLARD, Peter; BRADBURY, Robert H; PASS, Martin et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 6, pp 1633-1637, issn 0960-894X, 5 p.Article

Novel 4-anilinoquinazolines with C-6 carbon-linked side chains : Synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitorsHENNEQUIN, Laurent F. A; BALLARD, Peter; ROSS, Helen S et al.Bioorganic & medicinal chemistry letters (Print). 2006, Vol 16, Num 10, pp 2672-2676, issn 0960-894X, 5 p.Article

Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinaseBALLARD, Peter; BARLAAM, Bernard C; PEARSON, Stuart E et al.Bioorganic & medicinal chemistry letters (Print). 2007, Vol 17, Num 22, pp 6326-6329, issn 0960-894X, 4 p.Article